



NEWS RELEASE

# Agenus to Participate in Leerink Partners Global Biopharma Conference

2/26/2024

LEXINGTON, Mass.--(BUSINESS WIRE)-- Agenus Inc. ("Agenus") (Nasdaq: AGEN), a leader in discovering and developing novel immunological agents to treat various cancers, today announced that Dr. Garo Armen, Chairman and CEO, will participate in a fireside chat and investor one-on-ones at the upcoming Leerink Global Biopharma Conference on March 11<sup>th</sup> - 13<sup>th</sup> in Miami Beach, Florida. The fireside chat will take place at 2:30 p.m. ET on March 11<sup>th</sup>.

A live webcast and replay of the fireside chat will be accessible on the company's website at <https://investor.agenusbio.com/events-and-presentations>.

## About Agenus

Agenus is a leading immuno-oncology company targeting cancer and infectious diseases with a comprehensive pipeline of immunological agents. The company's mission is to expand patient populations benefiting from cancer immunotherapy through combination approaches, using a broad repertoire of antibody therapeutics, adoptive cell therapies (through MiNK Therapeutics) and adjuvants (through SaponiQx). Agenus is headquartered in Lexington, MA. For more information, visit [www.agenusbio.com](http://www.agenusbio.com) or [@agenus\\_bio](https://twitter.com/agenus_bio). Information that may be important to investors will be routinely posted on our website and social media channels.

## Investors

917-362-1370

[investor@agenusbio.com](mailto:investor@agenusbio.com)



## Media

781-674-4784

[communications@agenusbio.com](mailto:communications@agenusbio.com)

Source: Agenus Inc.